Journal
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 55, Issue 19, Pages 2049-2061Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2010.03.013
Keywords
atherosclerosis; osteoprotegerin; receptor activator of nuclear factor kappa B ligand; tumor necrosis factor-related apoptosis-inducing ligand; vascular calcification
Categories
Ask authors/readers for more resources
Osteoprotegerin (OPG) is a glycoprotein that acts as a decoy receptor for receptor activator of nuclear factor kappa B ligand (RANKL) and tumor necrosis factor-related apoptosis-inducing ligand. The OPG/RANKL/receptor activator of nuclear factor kappa B axis plays an important regulatory role in the skeletal, immune, and vascular systems. The protective role of OPG, in animal models, against vascular calcification has not been replicated in human trials; moreover, increased OPG levels have been consistently associated with the incidence and prevalence of coronary artery disease. There seems to be some dichotomy in the role of OPG, RANKL, and tumor necrosis factor-related apoptosis-inducing ligand in atherosclerosis and plaque stability. In this review, we integrate the findings from some of the important studies and try to draw conclusions with a view to gaining some insight into the complex interactions of the OPG/RANKL/receptor activator of nuclear factor kappa B axis and tumor necrosis factor-related apoptosis-inducing ligand in the pathophysiology of atherosclerosis. (J Am Coll Cardiol 2010;55:2049-61) (C) 2010 by the American College of Cardiology Foundation
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available